1
|
Hesselink JMK, Schatman ME. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. J Pain Res 2018; 11:2991-2995. [PMID: 30538538 PMCID: PMC6260176 DOI: 10.2147/jpr.s186082] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The repurposing of old drugs for new indications is becoming more accepted as a cost-efficient solution for complicated health problems. However, older drugs are often forgotten when they are not repositioned. This analysis makes a case for re-exploration of dermorphin for intrathecal use in postoperative pain and in a palliative context, with the goal of re-establishing this compound. Dermorphin was isolated from the skin of an Amazonian frog, characterized and identified as a bioactive heptapeptide by Vittorio Erspamer’s research group in the early 1980s. It was traditionally called “Kambo” or “Sapo” by Amazon tribes and was used to improve their physical and psychic skills as hunters. Its structure is rather enigmatic, containing a D-amino acid, and its pharmacological activity in a number of assays was found to be quite impressive and superior to morphine. Moreover, it has been established as more selective and potent with long-lasting analgesia compared to morphine after intracerebroventricular administration in animal models. In 1985, the first clinical trial results of a randomized, placebo-controlled study in postoperative pain were reported, and dermorphin administered via the intrathecal route was again impressively superior over the placebo and the reference compound morphine. This milestone study was apparently minimally read by clinicians, as the study has never been referenced; only 15 pharmacological and review papers after 1985 mentioned the results, with not one being a clinical paper. The interest in dermorphin decreased after 1985, and the compound was never again introduced in the clinical setting. Considering the enormous pressure to find superior acting opioids, this is quite puzzling. We suggest new clinical studies to further evaluate the safety and efficacy of dermorphin, especially administered via the intrathecal route in postoperative pain or for palliative use in terminal patients.
Collapse
Affiliation(s)
- Jan M Keppel Hesselink
- Department of Health, University of Witten/Herdecke, Witten, Germany, .,Institute for Neuropathic Pain, Bosch en Duin, the Netherlands,
| | - Michael E Schatman
- Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.,Research and Network Development, Boston Pain Care, Waltham, MA, USA
| |
Collapse
|
2
|
Guzevatykh LS, Voronina TA, Emel’yanova TG, Andreeva LA, Alfeeva LY, Seredenin SB, Myasoedov NF. Analgesic activity of dipeptide Tyr-Pro. BIOL BULL+ 2011. [DOI: 10.1134/s1062359008010081] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
3
|
ARLANDINI EMANUELE, BALLABIO MARZIA, CASTIGLIONE ROBERTO, GIOIA BRUNO, MALNATI MARIALUISA, PERSEO GIUSEPPE, RIZZO VINCENZO. Spectroscopic investigations on dermorphin and its [L-Ala2] analog. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1399-3011.1985.tb02144.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Gromovykh PS, Sokolov OY, Kost NV, Zozulya AA, Guzevatykh LS, Andreeva LA, Alfeeva LY, Shevchenko KV, Shevchenko VP, Nagaev IY, Myasoyedov NF. The use of tritium-labeled dermorphin for studying the interactions of C-terminal dermorphin fragment Tyr-Pro-Ser-NH2 and its stereoisomer Tyr-D-Pro-Ser-NH2 with opioid receptors. DOKLADY BIOLOGICAL SCIENCES : PROCEEDINGS OF THE ACADEMY OF SCIENCES OF THE USSR, BIOLOGICAL SCIENCES SECTIONS 2008; 419:104-106. [PMID: 18536274 DOI: 10.1134/s0012496608020105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2007] [Indexed: 05/26/2023]
Affiliation(s)
- P S Gromovykh
- Institute of Molecular Genetics, Russian Academy of Sciences, pl. Akademika Kurchatova 46, Moscow, 123182, Russia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Emel’yanova TG, Guzevatykh LS, Andreeva LA, Alfeeva LY, Myasoedov NF. The relationship between the structure of dermorphines and their thermoregulatory activity. BIOL BULL+ 2007. [DOI: 10.1134/s1062359007060106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Guzevatykh LS, Voronina TA, Emel’yanova TG, Andreeva LA, Gromovykh PS, Myasoedov NF, Seredenin SB. Comparative analysis of analgesic activities of dermorphin, [DPro6]-dermorphin, and their C-terminal tripeptides. BIOL BULL+ 2007. [DOI: 10.1134/s106235900705010x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Emel?yanova TG, Guzevatykh LS, Goryacheva NN, Andreeva LA, Alfeeva LY, Myasoedov NF. Study of thermoregulatory activity of a fragment of natural dermorphin precursor Arg-Dermorphin and its analogs. BIOL BULL+ 2005. [DOI: 10.1007/s10525-005-0007-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Cucumel K, Bagnol D, Moinier D, Fischer J, Conrath M, Cupo A. The rat dermorphin-like immunoreactivity is supported by an aminopeptidase resistant peptide. J Neuroimmunol 1998; 81:211-24. [PMID: 9521624 DOI: 10.1016/s0165-5728(97)00182-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Site-directed antibodies against synthetic related dermorphin peptides were previously produced and characterized. One of them, which specifically recognizes the crucial 'opioid message' (the N-terminal part of the dermorphin molecule (i.e. Tyr-D-Ala-Phe-Gly) was selected in order to detect and locate endogenous dermorphin-like molecules in rat, mouse and guinea pig tissues. Dermorphin-like peptides were found to be present in tissues known to contain peptides such as neurons in the central nervous system, nerve fibers in the gut and B and T immune cells. With all the tissues assayed, the HPLC profile obtained on the immunoreactive material showed the same main peak eluted at a retention time of 32 +/- 1 min. The results of biochemical experiments in which enzymatic treatments were performed on the dermorphin-like immunoreactivity indicate the immunoreactivity is a peptide resistant to aminopeptidase hydrolysis. This finding suggests the presence of a residue conferring resistance to proteolytic processes of this kind, which is likely to be a D-amino acid residue.
Collapse
Affiliation(s)
- K Cucumel
- Institut de Pharmacologie Moléculaire et Cellulaire CNRS-UPR411, Valbonne, France
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
1. In 1980, the skin of certain frogs belonging to the genus Phyllomedusinae was found to contain two new peptides that proved to be selective mu-opioid agonists. Given the name dermorphins, these were the first members of a peptide family that in the past 15 years has grown to reach a total of seven naturally occurring peptides and nearly 30 synthetic analogs. 2. Dermorphin peptides are potent analgesics in rodents and primates, including man. Some dermorphins can enter the blood-brain barrier and produce central antinociception after peripheral administration. 3. The dermorphin family also includes mu 1-opioid receptor selective agonists that produce intense opioid analgesia, but stimulate pulmonary ventilation. 4. Experiments in rats and mice chronically exposed to dermorphins have shown that not only do they have higher antinociceptive efficacy and potency than morphine, but they are also less likely than morphine to produce tolerance, dependence and opiate side effects.
Collapse
Affiliation(s)
- P Melchiorri
- Institute of Medical Pharmacology, University of Rome, La Sapienza, Italy
| | | |
Collapse
|
10
|
Emel'yanova TG, Usenko AB, Deigin VI, Yarova EP, Kamensky AA. Effect of dermorphin on thermoregulation in rats at selected ambient temperatures. Peptides 1996; 17:241-5. [PMID: 8801528 DOI: 10.1016/0196-9781(95)02132-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Intraperitoneal administration of dermorphin caused dose-dependent changes in rats core temperature and tail skin temperature (indicative of compensatory thermoregulatory vasoreactions in rats). The character of these changes depended strongly on the environmental temperature at which the inversion of the dermorphin-induced thermoregulatory effect was observed. In the cold environment (4-7 degrees C) dermorphin caused a significant, stable, dose-dependent hypothermia. In the thermoneutral environment (27-28 degrees C) dermorphin also caused hypothermia, but this effect was less pronounced. In the hot environment (31-32 degrees C) dermorphin caused hyperthermia. Dermorphin-induced changes in tail skin temperature indicate that dermorphin suppresses the thermoregulatory peripheral compensatory vasomotor reactions. Pretreatment with naloxone attenuated dermorphin-induced effects on core temperature and partially enhanced vasomotor effects of dermorphin. The data obtained indicate that dermorphin affects the core temperature regulation via mu-opiate receptors, whereas vasomotor effects of the peptide are probably mediated via naloxone-insensitive receptors.
Collapse
Affiliation(s)
- T G Emel'yanova
- N. N. Semenov Institute of Chemical Physics RAS, Department of Matter Structure, Moscow, Russia
| | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- V Erspamer
- Institute of Medical Pharmacology III, University La Sapienza, Città Universitaria, Rome, Italy
| |
Collapse
|
12
|
Sivanandaiah KM, Gurusiddappa S, Babu VV. Synthesis and biological studies of dermorphin and its analogs substituted at positions 5 and 7. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1989; 33:463-7. [PMID: 2570771 DOI: 10.1111/j.1399-3011.1989.tb00224.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Dermorphin and seven of its analogs substituted at positions 5 and/or 7, have been synthesized by the solid phase method employing mainly 9-fluorenylmethyloxycarbonylamino acid trichlorophenyl esters in presence of l-hydroxybenzotriazole, the solid support being the Merrifield resin. Among the analogs synthesized, the most interesting is [Tyr7]dermorphin. It is one of the most potent dermorphin analogs reported so far. Compared to the natural peptide, it is about two times more potent in the GPI (in vitro) and nearly 1.4 times more potent in its analgesic activity in mice by the hot plate test (in vivo). Further, its antidiarrhoeal activity in mice (in vivo) is comparable to that of dermorphin. On the other hand, [Thr7]dermorphin is almost as potent as dermorphin.
Collapse
Affiliation(s)
- K M Sivanandaiah
- Department of Chemistry, Central College, Bangalore University, India
| | | | | |
Collapse
|
13
|
Amiche M, Delfour A, Nicolas P. Structural requirements for dermorphin opioid receptor binding. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1988; 32:28-34. [PMID: 2906053 DOI: 10.1111/j.1399-3011.1988.tb00922.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Structural features influencing binding activity of dermorphin to opioid receptors have been investigated in the rat brain through the synthesis and evaluation of binding affinity of a series of synthetic dermorphin analogs. Tritiated dermorphin was used as primary ligand. The single population of high affinity dermorphin binding sites present in the rat brain is clearly of an opioid nature since bound radiolabeled dermorphin was fully displaced with high affinity either by morphine or naloxone. Displacement of tritiated dermorphin by all alkaloid opiates or dermorphin related peptides tested was monophasic, consistent with simple competitive inhibition at a single population of binding sites. Dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) was the most potent competitor in all experiments. The D-configuration of the amino acid residue in position 2 was found to be of crucial importance for binding. Replacement of D-Ala2 with L-Ala led to a deleterious effect, this analog being 1/5000th as potent as dermorphin in displacing bound tritiated dermorphin from its receptor. Shorter dermorphin homologs, dermorphin-(1-4)-NH2 and dermorphin-(1-3)-NH2, were found to be 20 and 40-fold less potent, respectively, than dermorphin. The C-terminal carboxamide function is of significant importance for manifestation of the full intrinsic binding potency of dermorphin. Deamidated dermorphin had 1/5th the potency of the parent peptide. This suggests that while the whole dermorphin sequence is required for the expression of the full intrinsic binding activity of the molecule, the N-terminal tripeptide is a key structure as it contains the features which allow receptor recognition.
Collapse
Affiliation(s)
- M Amiche
- Jacques Monod Institute, University of Paris, France
| | | | | |
Collapse
|
14
|
Zadina JE, Banks WA, Kastin AJ. Central nervous system effects of peptides, 1980-1985: a cross-listing of peptides and their central actions from the first six years of the journal Peptides. Peptides 1986; 7:497-537. [PMID: 3534808 DOI: 10.1016/0196-9781(86)90020-3] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A tabular synopsis is presented for articles concerned with the effects of peptides on the central nervous system that appeared in the journal Peptides from 1980-1985. A table arranged alphabetically by peptide and one arranged by effects, both listing routes of injection, species, direction of change, and qualifying notes, provides easy cross-referencing of peptides and their effects. Over 80 peptides and over 135 effects are listed. The list of peptides includes, but is not limited to: ACTH, angiotensin, bombesin, bradykinin, calcitonin, casomorphin, CCK, ceruletide, CGRP, CRF, dermorphin, DSIP, dynorphin, endorphins, enkephalins, GRF, gastrin, LHRH, litorin, metkephamid, MIF-l, motilin, MSH, NPY, NT, oxytocin, ranatensin, sauvagine, substances P and K, somatostatin, TRH, VIP, vasopressin, and vasotocin. The list of effects includes, but is not limited to: aggression, alcohol, analgesia, attention, avoidance, behavior, cardiovascular regulation, catalepsy, conditioned behavior, convulsions, dopamine binding and metabolism, discrimination, drinking, EEG, exploration, feeding, fever, gastric secretion, GI motility, grooming, learning, locomotor behavior, mating, memory, neuronal activity, open field, operant behavior, rearing, respiration, satiety, scratching, seizure, sleep, stereotypy, temperature, thermoregulation and tolerance.
Collapse
|
15
|
Sasaki Y, Hosono M, Matsui M, Fujita H, Suzuki K, Sakurada S, Sakurada T, Kisara K. On the degradation of dermorphin and D-Arg2-dermorphin analogs by a soluble rat brain extract. Biochem Biophys Res Commun 1985; 130:964-70. [PMID: 2862871 DOI: 10.1016/0006-291x(85)91709-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Degradation of dermorphin, [D-Arg2]dermorphin and [D-Arg2, Gly3, Phe4]dermorphin in a soluble rat brain extract was examined. The former two heptapeptides were degraded in a similar fashion to produce corresponding N-terminal tetrapeptide as the main degradation product along with the parallel release of Tyr5, Pro6 and Ser7-NH2. Tyr-D-Arg-Phe-Gly showed a good enzymatic stability. When captopril, an angiotensin-converting enzyme inhibitor, was present in the incubation mixture, hydrolysis of the Gly4-Tyr5 bond was markedly suppressed and resulted in release of the corresponding N-terminal hexapeptide as the main degradation product. Combined use of captopril and amastatin, an aminopeptidase inhibitor, markedly suppressed the hydrolysis of these peptides. On the other hand, [D-Arg2, Gly3, Phe4]dermorphin was hydrolyzed easier than the other two heptapeptides and considerable amounts of Tyr1 and Phe4 were released after 20 hr incubation while the N-terminal tetrapeptide, Tyr-D-Arg-Gly-Phe, showed a good enzymatic stability. On the basis of these results, possible degradation pathways of these heptapeptides were discussed.
Collapse
|
16
|
Cocchi D, Degli Uberti EC, Trasforini G, Salvadori S, Tomatis R, Torpia R, Perelli-Cippo R. Prolactin releasing and luteinizing hormone inhibiting activity of dermorphin shorter homologues in the rat. Life Sci 1985; 36:1707-13. [PMID: 3982229 DOI: 10.1016/0024-3205(85)90552-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Dermorphin, a heptapeptide isolated from the skin of the frogs Phillomedusa sauvagei and Phillomedusa rhodei, is endowed with potent peripheral and central opioid-like activity. Intracerebroventricular (icv) injection of dermorphin (31.2, 62.5 and 125 pmol/100g) induced in ovariectomized (OVX) rats dose related rises and decreases in prolactin (PRL) and luteinizing hormone (LH) levels, respectively. The aim of this work was to evaluate the same endocrine responses after administration of shorter peptide amide homologues, related to the N-terminal sequence of dermorphin. These compounds retain a substantial analgesic activity although the latter decreases with the decrease in the number of amino acid residues. Icv administration of the hexapeptide homologue (dermorphin 1-6 amide) to OVX rats did not induce any PRL rise or LH inhibition, even at the high dose of 250 pmol/100g. The pentapeptide (dermorphin 1-5 amide), instead, increased PRL and decreased LH secretion, although the effect was significant only at the dose of 250 pmol/100g. Administration of the tetrapeptide (dermorphin 1-4 amide) induced a significant PRL rise and LH inhibition at both the doses of 125 and 250 pmol/100g. The tetrapeptide was the smallest fragment of the dermorphin moiety which caused endocrine responses while the tripeptide (dermorphin 1-3 amide) was completely ineffective in this context. These data indicate that a complete dissociation exists between the behavioral and endocrine effects of the dermorphin homologues examined. In fact, shorter dermorphins whose analgesic potency was directly related to the number of amino acids, exhibited an opposite pattern in evoking endocrine effects.
Collapse
|
17
|
Cervini MA, Rossi AC, Perseo G, de Castiglione R. Antinociceptive and other opioid effects of a new series of dermorphin analogues after subcutaneous administration in the rat. Peptides 1985; 6:433-7. [PMID: 4070015 DOI: 10.1016/0196-9781(85)90109-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A series of hepta-, hexa-, penta- and tetrapeptide analogues of dermorphin have been evaluated in the rat for antinociceptive activity after subcutaneous (SC) administration at the screening dose of 4 mg/kg. Effective doses (ED50) were calculated for the most active compounds. Presence of spontaneous movements, defecation, micturition and corneal reflex were also recorded. Syntheses and analytical data of new derivatives are briefly reported.
Collapse
|
18
|
Abstract
A number of dermorphin analogues have been reviewed for antinociceptive activity after systemic administration. Analgesic peptides as potent as or more potent than dermorphin are found among the hepta- and tetrapeptide analogues, probably because of enhanced stability towards carboxyldipeptidases imparted by the Pro6 and D-Ala2 residues lying on the right and left side, respectively, of the point of cleavage. Hexapeptide analogues are practically inactive. [D-Arg2]derivatives are very potent, particularly in the tetrapeptide series. In binding studies dermorphin behaves as a pure opioid agonist, with a marked affinity and selectivity for the mu-type opioid receptors. In the heptapeptide analogues a direct correlation seems to exist between mu-selectivity and "sodium shift," and between lipophilicity and MVD/GPI potency ratio.
Collapse
|
19
|
Giagnoni G, Parolaro D, Crema G, Mennuni L, Brini A, Casiraghi L, Sala M, Gori E. Central pharmacological activities and opiate receptor binding studies of some dermorphin analogs. Peptides 1985; 6 Suppl 3:155-9. [PMID: 3008117 DOI: 10.1016/0196-9781(85)90367-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A series of dermorphin-like compounds were injected intracerebroventricularly in the rat to assess in vivo their effects on intestinal motility and analgesia. In vitro they were tested by binding assay using 3H-naloxone as radioligand or by guinea pig ileum bioassay. The synthetic peptides were less potent than dermorphin in inhibiting intestinal transit and in producing analgesia, or even inactive up to doses 30 times the dermorphin ED50. This reduction in pharmacological activity was coupled with a decrease in binding potency. The 3H-naloxone binding studies in the absence or presence of Na+ indicated that Na+ reduced the interaction of dermorphin and its analogs with brain opiate receptors. Only the dibenzyl derivative was slightly affected by sodium, suggesting a dual action for this peptide, as confirmed by preliminary data from guinea pig ileum bioassay.
Collapse
|